Sandler Howard M, Pienta Kenneth J
Rev Urol. 2003;5 Suppl 3(Suppl 3):S45-51.
Chemotherapy currently has an established role in the treatment of hormonere-fractory prostate cancer. There is strong evidence that combined-modality treatment, using androgen ablation in addition to radiotherapy, provides a benefit above and beyond radiotherapy alone in patients with a poor prognosis, perhaps due to the effect of androgen ablation on subclinical distant disease. Several clinical trials currently under way are investigating whether the addition of chemotherapy with known efficacy in the hormone-refractory setting can provide a survival advantage when used adjuvantly.
目前，化疗在激素难治性前列腺癌的治疗中已确立了其作用。有强有力的证据表明，对于预后较差的患者，采用雄激素剥夺联合放疗的综合治疗方式比单纯放疗更具优势，这可能是由于雄激素剥夺对亚临床远处疾病的影响。目前正在进行的几项临床试验正在研究，在激素难治性情况下已知有效的化疗药物辅助使用时能否带来生存优势。
